ArtVentive Medical Group, Inc. Announces Excellent Clinical Results and Expanded Enrollment in OCCLUDE I Post-Market Surveillance Study

CARLSBAD, Calif., Jul 31, 2014 (BUSINESS WIRE) ArtVentive Medical Group, Inc. (OTC Bulletin Board: AVTD) announced today excellent clinical results in conjunction with expanded enrollment in the ArtVentive Endoluminal Occlusion System, or ArtVentive EOS(TM) device, OCCLUDE I post-market surveillance study. The Department of Interventional Radiology and Neuroradiology, Medical University of Lublin, Poland reported successful results for eleven cases over a two-day period. Professor Tomasz Jargiello served as the Primary Investigator and Professor Malgorzata Szczerbo-Trojanowska, head of the Department, Dr. Krzysztof Pyra and Dr. Michal Sojka each participated in the study. In conjunction with the study, four female patients were treated for pelvic congestion syndrome and seven male patients were treated for varicoceles using the ArtVentive EOS(TM) device. The ArtVentive EOS(TM) device performed extremely well and met all expectations in a clinical setting, Dr. Jargiello stated. I was
http://bit.ly/1lgd4cY